Hypertrophic Cardiomyopathy

Cardiovascular·MeSH: Cardiomyopathy, Hypertrophic

18 drugs in development·10 companies·6 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
myqorzo	CYTOKINETICS INC (CYTK)

Phase 3(6)

Drug	Company
Aficamten	CYTOKINETICS INC (CYTK)
aficamten (5 mg	CYTOKINETICS INC (CYTK)
ck-3773274	CYTOKINETICS INC (CYTK)
Metoprolol succinate	CYTOKINETICS INC (CYTK)
metoprolol succinate (50 mg	CYTOKINETICS INC (CYTK)
Trientine	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(1)

Drug	Company
Ninerafaxstat 200mg MR	ARS Pharmaceuticals, Inc. (SPRY)

Phase 1(1)

Drug	Company
EDG-7500	Edgewise Therapeutics, Inc. (EWTX)

Preclinical(2)

Drug	Company
AVB-601	Solid Biosciences Inc. (SLDB)
myk-224	MyoKardia, Inc. (MYOK)

Unknown(1)

Drug	Company
approved hypertrophic cardiomyopathy drug treatments	BRISTOL MYERS SQUIBB CO (BMY)

Early Phase 1(1)

Drug	Company
Sotagliflozin	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(2)

Drug	Company
lx2022	Lexeo Therapeutics, Inc. (LXEO)
tn-201	Tenaya Therapeutics, Inc. (TNYA)

Phase 4(3)

Drug	Company
Mavacamten	BRISTOL MYERS SQUIBB CO (BMY)
MavacamtenRights	BRISTOL MYERS SQUIBB CO (BMY)
non-mavacamten symptomatic ohcm therapy	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 18 drugs in development for Hypertrophic Cardiomyopathy across 10 companies.

There are 6 clinical trials targeting Hypertrophic Cardiomyopathy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.